Tagged with R

Switzerland Switzerland’s healthcare system is at a crossroads. Although still one of the world’s bastions of biopharmaceutical innovation, the country’s domestic healthcare environment is under increasing pressure from rising costs, mounting drug shortages, and a regulatory environment that is slow to adapt. What role could pharmacies and the off-patent industry play…

Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…

Switzerland Martine Ruggli discusses the evolving role of pharmacists in Switzerland’s healthcare system, addressing challenges and opportunities in digitalization, drug shortages, and regulatory reforms, as well as the need to leverage pharmacists’ expertise more broadly.   Investing in and empowering pharmacists is essential for improving the quality, accessibility, and efficiency of…

Mexico Carlos Hernandez and Daniel Kilian discuss OECHSLER’s decision to diversify into the medical device industry, leveraging the company’s expertise in automotive manufacturing; how Mexico has become a crucial strategic hub for the group; and why the Mexican workforce, characterised by strong education and adaptability, has been a key factor in…

Mexico Valney Suzuki highlights his focus on expanding access to Novo Nordisk’s innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company’s groundbreaking semaglutide-based treatments for diabetes and obesity; and Mexico’s crucial role in Novo Nordisk’s global operations, not just as a market but also in…

Mexico Pedro Casas Alatriste of AmCham Mexico delves into the chamber’s efforts to enhance U.S.-Mexico trade relations, support key industries, and promote sustainable growth amid Mexico’s political transition.   We are entering North America 2.0, poised for renewed growth and collaboration What are the key issues the American Chamber of Commerce…

China Yoshio Uchida, President of Daiichi Sankyo China, outlines the company’s strategic focus on Antibody-Drug Conjugates (ADCs) within China’s oncology market and China’s relevant role in the company’s global R&D operations. He explains how Daiichi Sankyo is addressing the challenges of a dynamic healthcare environment while emphasizing the company’s commitment to…

Hong Kong Since we last covered Hong Kong in Summer 2023, the territory’s regulatory landscape has taken a major step towards its long-term goal of establishing a full regulatory authority. Having previously required approvals from two separate regulatory authorities in other countries or regions (such as the FDA in the US, the…

Hong Kong Hong Kong boasts some of Asia’s finest universities, with five ranking in the global top 100, and its two medical schools – at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK) – sitting in the global top 40. While this academic prowess produces globally…

Hong Kong Hong Kong needs to capitalise on its strong fundamentals to establish itself as a clinical research hotspot within APAC and support its transition into China’s innovation and technology hub. Does a new one-stop-shop for clinical trials across the Greater Bay Area hold the key?   Clinical trial numbers are skyrocketing…

Hong Kong Billed as China’s attempt to create an economic powerhouse to rival Silicon Valley, ‘The Greater Bay Area’ is a mega-region that includes nine cities in Guangdong province plus the Special Administrative Regions of Hong Kong and Macau. Since its launch in 2017, the GBA has worked to integrate these cities…

APAC A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest its China neurology and allergy business for USD 680 million; and Pfizer, AstraZeneca and Novartis investing in Singaporean manufacturing.  …